Bamirastine — predicted protein targets

Known targets — ChEMBL curated mechanism

ABCC9 ABL1 ACE ACHE ACVR1 ADORA1 ADORA2A ADORA2B ADORA3 ADRA1A ADRA1B ADRA1D ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 ADRB3 AGTR1 ALOX5 ATP4A ATP4B BCR BTK CACNA1A CACNA1B CACNA1C CACNA1D CACNA1E CACNA1F CACNA1G CACNA1H CACNA1I CACNA1S CACNA2D1 CACNA2D2 CACNA2D3 CACNA2D4 CACNB1 CACNB2 CACNB3 CACNB4 CACNG1 CACNG2 CACNG3 CACNG4 CACNG5 CACNG6 CACNG7 CACNG8 CALCRL CFB CHRM1 CHRM2 CHRM3 CHRM4 CHRM5 CHRNA1 CHRNB1 CHRND CHRNE CHRNG CRBN CUL4A CXCR1 CXCR2 DDB1 DDC DHFR DPP4 DRD2 DRD3 DRD4 EGFR ERBB2 ERBB4 ESR1 ESR2 FDPS FKBP1A FLT1 FLT3 FLT4 GART GHSR GRIA1 GRIA2 GRIA3 GRIA4 GRIK1 GRIK2 GRIK3 GRIK4 GRIK5 GRIN2A GSK3A GSK3B HDAC1 HDAC10 HDAC11 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HRH1 HTR1A HTR1B HTR1D HTR1E HTR1F HTR2A HTR2B HTR2C HTR3A HTR3B HTR3C HTR3D HTR3E HTR4 HTR5A HTR6 HTR7 IDH1 IDH2 IMPA1 ITGA2B ITGB3 JAK1 JAK2 JAK3 KCNJ11 KCNK3 KCNK9 KDR KIT MEN1 MET MMP1 MMP13 MMP7 MMP8 NA NOD2 NS5b ODC1 OPG057 OPRD1 OPRK1 OPRM1 P PARP1 PARP2 PDE3A PDE3B PDE4A PDE4B PDE4C PDE4D PDGFRB PIK3CA PIK3CB PIK3CD PIK3CG PIK3R1 PIK3R2 PIK3R3 PIK3R5 PKLR PPARD PPAT PTGS1 PTGS2 RBX1 ROCK1 ROCK2 RRM1 RRM2 RRM2B SCN10A SCN11A SCN1A SCN2A SCN3A SCN4A SCN5A SCN7A SCN8A SCN9A SCNN1A SCNN1B SCNN1G SIGMAR1 SLC10A2 SLC5A2 SLC6A2 SLC6A3 SLC6A4 SLC9A3 SYK TACR1 THRA THRB TOP1 TUBA1A TUBA1B TUBA1C TUBA3C TUBA3E TUBA4A TUBB TUBB1 TUBB2A TUBB2B TUBB3 TUBB4A TUBB4B TUBB6 TUBB8 TYK2 TYMS VDR ampC bla blaT-3 blaT-4 blaT-5 blaT-6 blaUOE-1 dacA dacB dacC folA folP ftsI gyrA gyrB ileS mecA mrcA mrcB mrdA parC parE pbp2 pbp4 pbpA pbpF rplA rplB rplC rplD rplE rplF rplI rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmC rpmD rpmE rpmE2 rpmF rpmG rpmG1 rpmG2 rpmG3 rpmH rpmI rpmJ rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsS rpsT rpsU thyA ykgM ykgO

The experimentally established mechanism targets of Bamirastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	CHRM2 known ✓	P08172	2/20	0.47

▸	HTR1A known ✓	P08908	2/20	0.47

▸	ADRA2A known ✓	P08913	2/20	0.47

▸	CHRM1 known ✓	P11229	2/20	0.47

▸	SLC6A2 known ✓	P23975	2/20	0.47

▸	ADRA1A known ✓	P35348	2/20	0.47

▸	DRD3 known ✓	P35462	2/20	0.47

▸	SLC6A3 known ✓	Q01959	2/20	0.47

▸	EGFR known ✓	P00533	1/20	0.47

▸	ERBB2 known ✓	P04626	1/20	0.47

▸	CHRM4 known ✓	P08173	1/20	0.47

▸	ADRB1 known ✓	P08588	1/20	0.47

▸	CHRM5 known ✓	P08912	1/20	0.47

▸	ADORA3 known ✓	P0DMS8	1/20	0.47

▸	ADRB3 known ✓	P13945	1/20	0.47

▸	DRD2 known ✓	P14416	1/20	0.47

▸	ADRA2B known ✓	P18089	1/20	0.47

▸	ADRA2C known ✓	P18825	1/20	0.47

▸	CHRM3 known ✓	P20309	1/20	0.47

▸	DRD4 known ✓	P21917	1/20	0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Bamirastine SCHEMBL5392309	0.99	PARP14 (0.61)	PARP14CHRM2HTR1AADRA2ACHRM1
SCHEMBL6619310	0.97	PARP14 (0.65)	PARP14CHRM2HTR1AADRA2ACHRM1
SCHEMBL6622189	0.94	PARP14 (0.56)	PARP14CHRM2HTR1AADRA2ACHRM1
Bamirastine SCHEMBL6616421	0.94	PARP14 (0.59)	PARP14CHRM2HTR1AADRA2ACHRM1
Bamirastine SCHEMBL7004964	0.93	PARP14 (0.55)	PARP14CHRM2HTR1AADRA2ACHRM1
Hydrochloric Acid SCHEMBL6617438	0.93	PARP14 (0.56)	PARP14CHRM2HTR1AADRA2ACHRM1
Hydrochloric Acid SCHEMBL6619604	0.93	PARP14 (0.58)	PARP14CHRM2HTR1AADRA2ACHRM1
SCHEMBL6618018	0.92	PARP14 (0.56)	PARP14CHRM2HTR1AADRA2ACHRM1
SCHEMBL7097307	0.91	PARP14 (0.65)	PARP14CHRM2HTR1AADRA2ACHRM1
SCHEMBL6624488	0.90	PARP14 (0.56)	PARP14CHRM2HTR1AADRA2ACHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-7235556-B2	Methods of treating dry eye disorders	ALCON, INC. (CH)	2007-06-26	—	—	US	claimed
US-20040254189-A1	Jnk inhibitors	TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)	2004-12-16	—	—	US	claimed
WO-2004093878-A1	USE OF FUSED PYRIDAZINE DERIVATIVES FOR TREATING DRY EYE DISORDERS	ALCON, INC. (CH)	2004-11-04	—	—	WO	claimed
US-20040209888-A1	Methods of treating dry eye disorders	ALCON, INC.	2004-10-21	—	—	US	claimed
US-20040137052-A1	mixture of a drug having anti-allergy, anti-histamine, anti-inflammatory, anti-PAF (platelet-aggregating factor) or eosinophile chemotaxis inhibiting activity and an acid; dosage form; excellent in the digestive tract absorbability and stability	TAKEDA CHEMICAL INDUSARIES LTD. (JP)	2004-07-15	—	—	US	claimed
EP-1426050-A1	JNK INHIBITORS	Takeda Chemical Industries, Ltd. (JP)	2004-06-09	—	—	EP	claimed
EP-1123936-B1	FUSED PYRIDAZINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF	TAKEDA CHEMICAL INDUSTRIES LTD (JP)	2003-12-10	—	—	EP	claimed
US-6627630-B1	Preventing or treating allergic skin diseases such as contact dermatitis, pruritus, dried dermatitis, acute urticaria prurigo and antiallergins	TAKEDA CHEMICAL INDUSTRIES, LTD. (JP)	2003-09-30	—	—	US	claimed
EP-1123936-A1	FUSED PYRIDAZINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF	Takeda Chemical Industries, Ltd. (JP)	2001-08-16	—	—	EP	claimed
US-20080207679-A1	Glutathione peroxidase mimetics for the treatment of dermatoses	BERKOWITZ NOAH	2008-08-28	—	—	US	disclosed
WO-2008100629-A2	GLUTATHIONE PEROXIDASE MIMETICS FOR THE TREATMENT OF DERMATOSES	SYNVISTA THERAPEUTICS, INC. (US)	2008-08-21	—	—	WO	disclosed
US-7235556-B2	Methods of treating dry eye disorders	ALCON, INC. (CH)	2007-06-26	—	—	US	disclosed
US-20040254189-A1	Jnk inhibitors	TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)	2004-12-16	—	—	US	disclosed
WO-2004093878-A1	USE OF FUSED PYRIDAZINE DERIVATIVES FOR TREATING DRY EYE DISORDERS	ALCON, INC. (CH)	2004-11-04	—	—	WO	disclosed
EP-1426050-A1	JNK INHIBITORS	Takeda Chemical Industries, Ltd. (JP)	2004-06-09	—	—	EP	disclosed
EP-1123936-B1	FUSED PYRIDAZINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF	TAKEDA CHEMICAL INDUSTRIES LTD (JP)	2003-12-10	—	—	EP	disclosed
US-6627630-B1	Preventing or treating allergic skin diseases such as contact dermatitis, pruritus, dried dermatitis, acute urticaria prurigo and antiallergins	TAKEDA CHEMICAL INDUSTRIES, LTD. (JP)	2003-09-30	—	—	US	disclosed
EP-1243271-A1	NASAL DROPS CONTAINING FUSED PYRIDAZINE DERIVATIVES	Takeda Chemical Industries, Ltd. (JP)	2002-09-25	—	—	EP	disclosed
EP-1123936-A1	FUSED PYRIDAZINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF	Takeda Chemical Industries, Ltd. (JP)	2001-08-16	—	—	EP	disclosed
JP-2000191664-A	CONDENSED PYRIDAZINE DERIVATIVE, ITS PRODUCTION AND USE	TAKEDA CHEM IND LTD	2000-07-11	—	—	JP	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20040254189-A1	Jnk inhibitors	AR, MAPK1, MAPK3	CHRM2 4345/4885HTR1A 921/4885ADRA2A 220/4885
US-20040137052-A1	mixture of a drug having anti-allergy, anti-histamine, anti-inflammatory, anti-PAF (platelet-aggregating factor) or eosinophile chemotaxis inhibiting activity and an acid; dosage form; excellent in the digestive tract absorbability and stability	PLA2G7, HRH2, PAFAH1B2	CHRM2 1941/4885HTR1A 1864/4885ADRA2A 968/4885
US-20080207679-A1	Glutathione peroxidase mimetics for the treatment of dermatoses	GPX1, GPX4, GGT1	CHRM2 4798/4885HTR1A 3929/4885ADRA2A 4540/4885
US-20040209888-A1	Methods of treating dry eye disorders	HRH2, PNPO, AQP4	CHRM2 114/4885HTR1A 1041/4885ADRA2A 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.